Extrait

1) To demonstrate the non-inferiority of the immune response to D-QIV (FLU D-QIV) in terms of HI antibody titres at Day 28 after D-QIV vaccination, for each influenza virus strain, when co-administered with or administered separately from PPV23 (Pneumovax 23). 2) To demonstrate the non-inferiority of the humoral immune response to PPV23 in terms of anti-pneumococcal antibody concentrations at 28 days after administration of the pneumococcal vaccine, for six pneumococcal serotypes (1, 3, 4, 7F, 14, 19A) , when co administered with or administered separately from D-QIV.

Critère d'inclusion

• The target population for this study is adults in stable health ≥ 50 years of age at risk for complications of influenza and pneumococcal diseases

Liens

• ictrp
• ictrp
• euctr
• euctr